Chinese company Livzon Pharmaceutical Group has reached an agreement to sell its Pharma Firm.

The consideration for the acquisition is fixed at ¥4.55bn ($661.1m).

Speciality pharmaceutical company PLx Pharma has merged with Dipexium Pharmaceuticals.

The combined entity will operate under the name PLx Pharma and will continue to be led by PLx’s management team.

The issued and outstanding shares of common stock of Dipexium Pharmaceuticals saw a reverse stock split at the ratio of one-for-eight, as part of the merger.

"Speciality pharmaceutical company PLx Pharma has merged with Dipexium Pharmaceuticals."

Tunisian pharmaceutical company Medis Laboratories has completed the acquisition of Sanofi’s subsidiary, Winthrop Pharma Senegal (Winthrop Pharma Tunisie).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The target company is also a pharmaceutical company based in Tunisia.

Through the acquisition, the acquirer company intends to develop the business in Francophone Sub-Saharan Africa from a Senegalese base.

Japanese generic drug manufacturer Sawai Pharmaceutical has reached an agreement with Acovato to acquire the generic pharmaceutical business of its subsidiary, Upsher-Smith Laboratories.

The purchase consideration for the acquisition is agreed to be $1.05bn, which Sawai plans to fund through bank loans and cash in hand.